U.S. markets open in 1 hour 12 minutes
  • S&P Futures

    4,366.75
    +23.50 (+0.54%)
     
  • Dow Futures

    33,986.00
    +188.00 (+0.56%)
     
  • Nasdaq Futures

    15,073.25
    +49.25 (+0.33%)
     
  • Russell 2000 Futures

    2,195.70
    +14.80 (+0.68%)
     
  • Crude Oil

    71.44
    +0.95 (+1.35%)
     
  • Gold

    1,774.20
    -4.00 (-0.22%)
     
  • Silver

    22.72
    +0.10 (+0.46%)
     
  • EUR/USD

    1.1730
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    22.81
    -2.90 (-11.28%)
     
  • GBP/USD

    1.3636
    -0.0029 (-0.21%)
     
  • USD/JPY

    109.5600
    +0.3400 (+0.31%)
     
  • BTC-USD

    41,996.10
    -1,260.07 (-2.91%)
     
  • CMC Crypto 200

    1,043.27
    -20.58 (-1.93%)
     
  • FTSE 100

    7,070.12
    +89.14 (+1.28%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Orchard Therapeutics, Pharming Ink Development Pact For Gene Therapy

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Orchard Therapeutics plc (NASDAQ: ORTX) and Pharming Group NV (NASDAQ: PHAR) have collaborated to research, develop, manufacture and commercialize OTL-105 for hereditary angioedema (HAE).

  • OTL-105 is an investigational autologous hematopoietic stem cell (HSC) gene therapy designed to increase C1 esterase inhibitor (C1-INH) in HAE patient serum to prevent hereditary angioedema attacks.

  • OTL-105 inserts one or more functional copies of the SERPING1 gene into patients' HSCs ex vivo, which are then transplanted back into the patient for potential durable C1-INH production.

  • Under the terms of the collaboration, Pharming has worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings, and commercialization.

  • Orchard will lead the IND-enabling activities and oversee the manufacturing of OTL-105 during pre-clinical and clinical development, which Pharming will fund.

  • In addition, both companies will explore the application of a non-toxic conditioning regimen for use with OTL-105 administration.

  • Orchard will receive an upfront payment of $17.5 million comprising $10 million in cash and a $7.5-million equity investment.

  • Orchard is also eligible to receive up to $189.5 million in milestone payments and royalty payments on future worldwide sales.

  • ORTX, PHAR Price Action: ORTX shares were down 2.16% at $4.30 at last check Thursday, while PHAR shares were up 2.34% at $11.53.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.